The Redwood City, CA-based company was all set to go public. However, the negative impact of COVID-19 on the market caused Pulmonx to switch gears. Now the firm has raised $66 million to push the commercialization of its minimally invasive treatment for severe emphysema.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,